ERBB2 and breast carcinoma: For the first time, serum VISTA levels were evaluated in a diseased population, and queens diagnosed with the most aggressive mammary carcinoma subtypes, HER2-positive or triple-negative [6], revealed higher serum VISTA expression levels (p = 0.0025 and p = 0.0019, respectively).